Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Lupin consolidated net profit rises 89.04% in the March 2026 quarter
Sales rise 32.90% to Rs 7391.91 crore
Lupin shares may react to record US sales in Q4, strong operating performance
Lupin's India market sales increased by 11% to ₹1,908.2 crore from ₹1,711.3 crore last year. However, it declined sequentially from the ₹2,038.7 crore figure.
Stocks To Watch Today: Dabur, Britannia Industries, BSE, Mahnagar Gas, Lupin, Titan, SBI, Swiggy, MCX & More
Here's a look at stocks that are likely to be in focus during the trading session on Friday.
Lupin Q4 Results: Profit Soars 90%, Revenue Nears Rs 7,500 Crore; Highest-Ever Dividend Declared
Consolidated revenue of Lupin advanced by 31.9% year-on-year for the three months ended March, reaching Rs 7,475 crore in comparison to Rs 5,667 crore.
Q4 Results LIVE Updates: Bajaj Auto reacts to earnings beat, buyback; Lupin, Biocon report today
Q4 Results LIVE Updates: Bajaj Auto reacts to results, along with platform stocks Meesho, Paytm and PB Fintech. Britannia, Lupin, Biocon, Bharat Forge among eight F&O names report results today. Watch this space for all the LIVE updates.
Bharat Forge, Biocon, Dabur, Escorts Kubota, Lupin, MRF, Pidilite Industries Q4 Results Today — Earning Estimates
Bharat Forge is expected to report profit at Rs 369.8 crore and revenue at Rs 4,559.97 crore.
Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.
Q4 Results This Week: L&T, BHEL among 120-plus companies set to report numbers
From Nifty 50 names like Larsen & Toubro, Mahindra & Mahindra, Titan, Bajaj Auto, Tata Consumer, to important broader market names like BHEL, Manappuram Finance, Lupin, Petronet LNG, Urban Company, Paytm and others, these companies will be reporting their March quarter results over the course of this upcoming week.
Here's why shares of Lupin and Zydus Life are under pressure on Tuesday
Analysts believe the MSN settlement could open the door for additional generic entrants. An early launch by MSN may impact earnings estimates for both Lupin and Zydus for FY27.
Lupin launches generic anti-diabetic tablets in US
Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydrochloride extended-release tablets. The US Food and Drug Administration approved the drug. Lupin's product is bioequivalent to Xigduo XR. This launch offers a new treatment option for diabetic patients in the US.
Lupin Launches Generic Diabetes Drug in US | Just Dial Q4 FY26 Results | Top Buzzing Stocks Today - Equitymaster
Lupin Launches Generic Diabetes Drug in US | Just Dial Q4 FY26 Results | Top Buzzing Stocks TodayEquitymaster
Buy, Sell Or Hold: Lupin, IDFC First Bank, Eicher Motors, IRFC, Eternal, Coal India — Ask Profit
Ruchit Jain and Avinash Gorakshakar provided insights on these investor queries and more on NDTV Profit's Ask Profit's show.